SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported) December 11, 2003
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 000-23265 | 94-3267443 | |
| (Commission file Number) | (IRS Employer ID Number) |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (919) 862-1000
| Item 5. | Other Events and Regulation FD Disclosure |
On December 11, 2003, Salix Pharmaceuticals, Ltd. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has permitted clinical trials to initiate under the Company’s recently filed Investigational New Drug (IND) for Granulated Mesalamine. A copy of this press release is attached.
| Item 7. | Financial Statements and Exhibits. |
(c) Exhibits
| Exhibit No. | Description | |
99.1 | Press release dated December 11, 2003 of Salix Pharmaceuticals, Ltd., announcing that the U.S. Food and Drug Administration (FDA) has permitted clinical trials to initiate under the Company’s recently filed Investigational New Drug (IND) for Granulated Mesalamine. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD. | ||||||||
| Date: December 11, 2003 | By: | /s/ Adam C. Derbyshire | ||||||
Adam C. Derbyshire Senior Vice President and Chief Financial Officer | ||||||||
